snx-2112 has been researched along with Leukemia--Myelogenous--Chronic--BCR-ABL-Positive* in 1 studies
1 other study(ies) available for snx-2112 and Leukemia--Myelogenous--Chronic--BCR-ABL-Positive
| Article | Year |
|---|---|
Transcriptomic and proteomic approach to studying SNX-2112-induced K562 cells apoptosis and anti-leukemia activity in K562-NOD/SCID mice.
SNX-2112, a novel inhibitor of Hsp90 currently used as an anti-tumor drug, induces apoptosis in multiple tumor cell lines. It destabilizes specific client proteins, but the molecular mechanism of the apoptosis effect of SNX-2112 is poorly understood. Here, we analyzed the apoptotic effect of SNX-2112 on human chronic myeloid leukemia (CML) K562 cells. Transcriptomic and proteomic approaches further revealed that caspase signals originated from mitochondria dysfunction, mediated by Akt signaling pathway inactivity. Additionally, SNX-2112 prolonged the survival time of NOD/SCID mice inoculated with K562 tumor cells. Our results demonstrated the therapeutic potential of SNX-2112 against human CML. Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-Associated Death Protein; bcl-X Protein; Gene Expression Profiling; Heterocyclic Compounds, 4 or More Rings; HSP90 Heat-Shock Proteins; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Potential, Mitochondrial; Mice; Mice, Inbred NOD; Mice, SCID; Mitochondria; Mitochondrial Proteins; Neoplasm Proteins; Neoplasm Transplantation; Proteomics; Signal Transduction; Transplantation, Heterologous | 2009 |